Neurotrophic Peptides: Brain Growth Factors Explained
Brain Neurotrophic Factors
4 families of neurotrophins
BDNF, NGF, NT-3, and NT-4/5 form the classical neurotrophin family. Together with GDNF and CNTF, they regulate the survival, growth, and connectivity of billions of neurons.
Multiple sources
Multiple sources
View as imageYour brain contains roughly 86 billion neurons, and every one of them depends on peptide growth factors to survive, form connections, and adapt to experience. These neurotrophic peptides, including BDNF, NGF, GDNF, and CNTF, are not just developmental signals that wire the brain during childhood. They remain active throughout adult life, maintaining synaptic plasticity, supporting neuronal repair, and determining which neural circuits strengthen and which wither. When neurotrophic signaling declines, as it does in aging, Alzheimer's disease, Parkinson's disease, and depression, the consequences include neuronal death, synaptic loss, and cognitive impairment. Understanding these peptides is the foundation for understanding why the brain degrades and what peptide-based approaches exist to slow or reverse that process.
Key Takeaways
- BDNF is the most abundant neurotrophin in the adult brain, concentrated in the hippocampus and cortex, where it drives synaptic plasticity and memory consolidation through TrkB receptor signaling
- NGF supports basal forebrain cholinergic neurons that degenerate in Alzheimer's disease; recombinant NGF (cenegermin) is FDA-approved for neurotrophic keratitis
- GDNF is the primary survival factor for dopaminergic neurons that die in Parkinson's disease; a peptide nanostructure mimicking GDNF rescued dopaminergic neurons in vitro[3]
- GLP-1 receptor agonists increase BDNF expression through CREB activation, representing a pharmacological bridge between metabolic peptides and neurotrophic signaling[2]
- Cerebrolysin, a peptide mixture containing neurotrophic fragments, upregulates BDNF and protects neurons through TrkB-PI3K/Akt signaling[4]
- Semax, a synthetic ACTH(4-10) analog, shows neuroprotective effects in Alzheimer's models through modulation of neurotrophic pathways[7]
The Neurotrophin Family
The classical neurotrophins share a common structural motif: a cystine knot that creates a stable homodimer capable of binding two classes of receptors. The tropomyosin receptor kinase (Trk) family provides specific, high-affinity signaling. The p75 neurotrophin receptor (p75NTR) provides lower-affinity signaling that can promote either survival or death depending on cellular context.
BDNF: The Master Plasticity Factor
Brain-derived neurotrophic factor is the most studied neurotrophin in the adult brain. Concentrated in the hippocampus, cortex, and cerebellum, BDNF binds TrkB receptors to activate three downstream cascades: the MAPK/ERK pathway (promoting synaptic plasticity and gene expression), the PI3K/Akt pathway (promoting cell survival), and the PLCgamma pathway (regulating calcium signaling and synaptic transmission).
BDNF does more than keep neurons alive. It is the molecular currency of learning and memory. Long-term potentiation (LTP), the cellular mechanism of memory formation, requires BDNF release at activated synapses. Exercise increases BDNF expression in the hippocampus. Depression is associated with reduced BDNF levels, and antidepressants increase BDNF signaling. Xu et al. (2026) provided molecular evidence that GLP-1 receptor agonists increase BDNF expression through CREB (cAMP response element-binding protein) activation, linking metabolic peptide drugs to neurotrophic signaling.[2] This connection explains growing interest in GLP-1 agonists for neurodegenerative diseases.
The therapeutic challenge with BDNF is delivery. The protein is 27 kDa, does not cross the blood-brain barrier, and has a short half-life when injected peripherally. Ugalde-Trivino et al. (2025) developed a brain-accessible peptide that modulates stroke-related neuroinflammation by targeting the BDNF-TrkB signaling axis, demonstrating that smaller peptide fragments derived from the BDNF pathway can achieve what full-length BDNF cannot.[6]
NGF: The Original Neurotrophin
Nerve growth factor was the first neurotrophin discovered, earning Rita Levi-Montalcini the Nobel Prize in 1986. NGF binds TrkA receptors on sensory neurons and basal forebrain cholinergic neurons. The cholinergic neurons of the nucleus basalis of Meynert are among the first to degenerate in Alzheimer's disease, and their loss correlates directly with cognitive decline.
NGF gene therapy and protein delivery to the basal forebrain have been tested in Alzheimer's clinical trials with mixed results. The protein itself has been more successful in ophthalmology: recombinant human NGF (cenegermin/Oxervate) is FDA-approved for neurotrophic keratitis, a corneal disease caused by impaired trigeminal nerve function. This remains one of only two neurotrophic peptide products approved for clinical use.
GDNF: The Dopaminergic Factor
Glial cell line-derived neurotrophic factor is the primary survival signal for midbrain dopaminergic neurons, the cells that die in Parkinson's disease. GDNF binds the GFRalpha1 co-receptor, activating the RET tyrosine kinase to promote dopaminergic neuron survival, axonal growth, and dopamine synthesis.
Clinical trials of direct GDNF infusion into the putamen of Parkinson's patients have produced inconsistent results: some patients showed dramatic improvement, others showed none, and the delivery method (chronic brain infusion through an implanted catheter) presents practical challenges. Carballo-Molina et al. (2025) took a different approach, designing a supramolecular peptide nanostructure that mimics GDNF's trophic effects without using the full protein.[3] This peptide-based scaffold promoted survival and differentiation of human dopaminergic neurons in vitro, suggesting that engineered peptide mimetics could replicate GDNF signaling without the delivery problems of the native protein.
CNTF: The Glial Factor
Ciliary neurotrophic factor acts primarily through glial cells rather than neurons directly. CNTF binds a tripartite receptor complex (CNTFRalpha, LIFRbeta, gp130) that activates JAK/STAT signaling. In the brain, CNTF promotes astrocyte differentiation and oligodendrocyte survival. In the retina, it supports photoreceptor survival through Muller glial intermediaries.
CNTF is the other approved neurotrophic product: the NT-501 encapsulated cell technology implant delivers continuous CNTF into the vitreous for retinal degenerative diseases. Systemic CNTF administration was tested for ALS but failed due to dose-limiting side effects (weight loss, muscle wasting at high systemic doses). The lesson: neurotrophic factors often require local delivery to achieve therapeutic concentrations without systemic toxicity.
How Neurotrophic Decline Drives Disease
The connection between neurotrophic deficiency and brain disease is not speculative. Alzheimer's disease brains show reduced BDNF and NGF in the hippocampus and basal forebrain, respectively. The magnitude of BDNF reduction correlates with the severity of cognitive impairment. Parkinson's disease brains show reduced GDNF in the substantia nigra, the region where dopaminergic neurons die. Depression is associated with lower serum BDNF levels that normalize with successful treatment, leading to the "neurotrophin hypothesis of depression" in which reduced neurotrophic support impairs hippocampal neurogenesis and synaptic plasticity.
Age-related neurotrophic decline begins in the fourth decade. By age 70, BDNF levels in the hippocampus have decreased by approximately 30-50% compared with young adults. This decline mirrors the trajectory of age-related memory impairment. Exercise partially reverses the decline (running increases hippocampal BDNF in both rodents and humans), which is one reason physical activity is the single most evidence-based intervention for age-related cognitive decline. But exercise cannot fully compensate for the neurotrophic deficit in disease states, which is why pharmacological approaches are pursued.
The clinical implication is that restoring neurotrophic signaling is not simply adding a missing ingredient. The decline in neurotrophins is both a cause and a consequence of neurodegeneration: neurons that lack trophic support die, and dying neurons release less neurotrophic factor, creating a degenerative spiral. Breaking this cycle requires delivering neurotrophic signals before the target neurons are lost.
Peptide-Based Neurotrophic Therapeutics
Because full-length neurotrophins are too large to cross the blood-brain barrier and too unstable for systemic delivery, several peptide-based strategies have emerged.
Cerebrolysin: A Neurotrophic Peptide Mixture
Cerebrolysin is a brain-derived peptide preparation containing enzymatically processed fragments of multiple neurotrophic proteins. P et al. (2024) demonstrated that cerebrolysin protects neurons through upregulation of BDNF and activation of the TrkB-PI3K/Akt survival pathway.[4] When combined with citicoline, cerebrolysin showed synergistic neuroprotection in an animal model of cognitive impairment.
Seidl et al. (2024) compared the biological activity and composition of cerebrolysin with other peptide preparations and found that cerebrolysin's neurotrophic effects stem from its unique mixture of low-molecular-weight peptides and free amino acids derived from porcine brain tissue.[5] The preparation contains fragments that mimic BDNF, NGF, and CNTF activity, providing a multi-target neurotrophic effect that single-peptide approaches cannot match. Cerebrolysin has been tested in stroke, traumatic brain injury, and Alzheimer's disease clinical trials.
Semax: A Synthetic Neurotrophic Peptide
Semax is a synthetic heptapeptide analog of ACTH(4-10) that has neurotrophic properties independent of its parent hormone's adrenal effects. Radchenko et al. (2025) reviewed Semax's potential for correcting pathological impairments in Alzheimer's disease models.[7] Semax increases BDNF expression, modulates inflammatory pathways, and enhances cholinergic neurotransmission in the hippocampus. Unlike full-length neurotrophins, Semax is a small peptide (7 amino acids) that can be administered intranasally and has demonstrated brain penetration in preclinical studies.
GLP-1 Agonists: Metabolic Peptides as Neurotrophic Agents
The most unexpected entry in the neurotrophic therapeutic space comes from metabolic peptide drugs. Athauda et al. (2026) reviewed the promise of GLP-1 receptor agonists for neurodegenerative diseases, noting that preclinical studies across Alzheimer's, Parkinson's, Huntington's, and ALS models consistently show neuroprotection.[1] The mechanisms include reduction of neuroinflammation, enhancement of mitochondrial function, promotion of autophagy, and upregulation of BDNF through CREB signaling.[2]
Human clinical trials are now testing liraglutide and semaglutide for Alzheimer's disease and Parkinson's disease. Epidemiological data from millions of diabetic patients suggests lower rates of neurodegenerative disease in GLP-1 RA users compared with other antidiabetic agents. If these peptide drugs prove neuroprotective in dedicated neurological trials, they would become the first systemically delivered neurotrophic agents to reach clinical use for brain diseases.
Engineered Peptide Fragments
Rehra et al. (2026) demonstrated brain delivery of a neurotrophic peptide derived from the secreted amyloid precursor protein APPsalpha.[8] APPsalpha is a neuroprotective fragment of the same protein that, when cleaved differently, produces the toxic amyloid-beta peptide of Alzheimer's disease. Delivering APPsalpha-derived peptides to the brain represents a strategy of boosting the protective pathway while the disease process amplifies the destructive one. Similarly, Dihexa, a small peptide derived from angiotensin IV, modulates hepatocyte growth factor signaling to promote synaptogenesis through a pathway distinct from classical neurotrophins.
Sharma et al. (2026) showed that a synthetic peptide (DP1) derived from an antimicrobial peptide framework reduced neuroinflammation-associated brain damage and cognitive decline, demonstrating that peptides designed for other purposes can be repurposed as neurotrophic agents when they happen to modulate the right inflammatory pathways.[9]
Why Neurotrophic Therapy Is Hard
The gap between understanding neurotrophic peptides and using them clinically is explained by three persistent barriers:
The blood-brain barrier. BDNF, NGF, GDNF, and CNTF cannot cross it at therapeutic concentrations. Smaller peptide mimetics, intranasal delivery, gene therapy, and encapsulated cell implants are all workarounds, but none is a general solution.
Pleiotropic effects. Neurotrophins do different things in different cell types. NGF promotes survival of cholinergic neurons but also activates pain-sensing nociceptors (why NGF clinical trials for Alzheimer's caused pain). CNTF supports neurons locally but causes cachexia systemically. Achieving therapeutic neurotrophic signaling in the target tissue without off-target effects remains the central challenge.
Dosing precision. Too little neurotrophin has no effect. Too much can be toxic: excess BDNF promotes epileptiform activity, and overactive TrkB signaling has been linked to anxiety. The brain's endogenous neurotrophic system operates within narrow concentration ranges, and therapeutic interventions must match that precision.
These barriers explain why only two neurotrophic products are approved (cenegermin for the eye, CNTF implant for the retina), both for accessible tissues that bypass the blood-brain barrier. Brain-targeted neurotrophic therapy remains the field's central unsolved problem.
The Bottom Line
Neurotrophic peptides (BDNF, NGF, GDNF, CNTF) are essential for neuronal survival, synaptic plasticity, and brain maintenance throughout life. Their decline contributes to Alzheimer's, Parkinson's, depression, and age-related cognitive impairment. Therapeutic strategies include peptide mixtures (cerebrolysin), synthetic analogs (Semax), peptide nanostructures mimicking GDNF, brain-accessible peptide fragments, and metabolic peptides (GLP-1 agonists) that boost endogenous BDNF. The blood-brain barrier remains the primary obstacle to clinical translation for brain targets, though peptides designed for the eye have reached approval.